Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 13/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025893 | 0.90 | P2RX7 (0.38) | P2RX7GRIN2C | |
| SCHEMBL13822114 | 0.85 | HCRTR1 (0.33) | HCRTR1HCRTR2 | |
| SCHEMBL10025895 | 0.78 | ALDH1A1 (0.39) | GRIN2C | |
| SCHEMBL13809241 | 0.77 | GRIN2C (0.41) | P2RX7HCRTR1HCRTR2GRIN2C | |
| SCHEMBL13809243 | 0.75 | KIF11 (0.53) | P2RX7HCRTR1HCRTR2GRIN2C | |
| SCHEMBL13822083 | 0.72 | TSHR (0.33) | NOTUM | |
| SCHEMBL10025896 | 0.72 | PTGDR2 (0.46) | P2RX7 | |
| SCHEMBL10025901 | 0.70 | PDE5A (0.39) | — | |
| SCHEMBL10025913 | 0.70 | PDE5A (0.39) | — | |
| SCHEMBL10025897 | 0.68 | P2RX7 (0.35) | P2RX7GRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124616-B2 | Bicyclic PPAT inhibitors as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-28 | — | — | US | disclosed |
| US-8124616-B2 | Bicyclic PPAT inhibitors as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-28 | — | — | US | disclosed |
| US-20090203730-A1 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | MAXTHERA INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203730-A1 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | MAXTHERA INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009073534-A2 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | MAXTHERA INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203730-A1 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | APRT, PPA1, GNPAT | P2RX7 1334/4885HCRTR1 3981/4885HCRTR2 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.